Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Su-11248 Sugen.

Kathleen M Sakamoto1

  • 1Division of Hematology-Oncology, Mattel Children's Hospital, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1752, USA. kms@ucla.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|January 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.

Leukemia·2026
Same author

Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.

Leukemia·2026
Same author

Longitudinal Single-Cell RNA-Sequencing Reveals Evolution of Micro- and Macro-states in Chronic Myeloid Leukemia.

Cancer research·2026
Same author

DHODH as a targetable metabolic Achilles' heel for chemotherapy-resistant B-ALL.

Blood·2026
Same author

Inflammatory pathways and the bone marrow microenvironment in inherited bone marrow failure syndromes.

Stem cells (Dayton, Ohio)·2025
Same author

Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

bioRxiv : the preprint server for biology·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

SUGEN is developing SU-11248, an oral tyrosine kinase (TK) inhibitor targeting platelet-derived growth factor and other TK pathways for cancer treatment. Phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were ongoing in October 2003.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase (TK) signaling pathways play a critical role in cancer cell proliferation and survival.
  • Inhibitors targeting TKs are a promising strategy for anticancer drug development.
  • SU-11248 is an orally active small molecule designed to inhibit multiple TKs.

Purpose of the Study:

  • To evaluate SU-11248, an orally active tyrosine kinase inhibitor, as a potential anticancer therapeutic.
  • To assess the efficacy of SU-11248 in patients with gastrointestinal stromal tumors (GIST) and renal cell carcinoma (RCC).

Main Methods:

  • Development of SU-11248, an orally active inhibitor targeting platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways.
  • Initiation of Phase III clinical trials to evaluate SU-11248 in patients with GIST and RCC.

Related Experiment Videos

Main Results:

  • By October 2003, Phase III trials for gastrointestinal stromal tumors were underway.
  • By October 2003, Phase III trials for renal cell carcinoma were underway.

Conclusions:

  • SU-11248 demonstrates potential as an anticancer agent targeting key TK signaling pathways.
  • Ongoing Phase III trials will determine the clinical utility of SU-11248 for GIST and RCC treatment.